Dr. Nabors joins Appili effective April 3, 2023, and will lead the advancement of programs through development, regulatory submission and key commercialization milestones.
Dr. Nabors joins Appili from Integrated BioTherapeutics Inc. where, in his role as executive vice president and Chief Development Officer, he was responsible for leading the company's vaccine and immunotherapeutic candidates through bioanalytical development, IND-enabling studies, GMP manufacturing and into clinical studies.
Prior to that he served as president of DynPort Vaccine company Inc. (a subsidiary of General Dynamics) where he was responsible for the overall success of the company, overseeing P&L responsibility and 800 staff, and establishing the technical, strategic, and regulatory direction for all projects in the company's portfolio.
Over his accomplished 25-year career, Dr. Nabors has also held progressively senior roles with Sanofi Pasteur, Emergent BioSolutions, and the National Biodefense Analysis and Countermeasures Center (NBACC) within the US Department of Homeland Security.
He has played a central role in product development from pre-clinical stages through to Phase 3, for development of vaccines and therapeutics for pediatric, adult, and biodefense markets.
He has also managed corporate subsidiaries of 120 employees, served on executive-level management committees and presented before Food and Drug Administration advisory committees.
Dr. Nabors will be representing Appili at the World Vaccine Congress, the premier event for R&D and strategic partnering for the global vaccine industry, in Washington, DC, from April 3rd to 6th, 2023.
Dr. Nabors will be participating in scientific sessions to identify current trends in vaccine development and to network with key contacts that Appili may be able to work with to help advance its programs.
Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections.
By systematically identifying urgent infections with unmet needs, Appili's goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives.
The company is currently advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections.
Led by a proven management team, Appili is at the epicenter of the global fight against infection.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer